TW-37

Catalog No.S1121

For research use only.

TW-37 is a novel nonpeptide inhibitor to recombinant Bcl-2, Bcl-xL and Mcl-1 with Ki of 0.29 μM, 1.11 μM and 0.26 μM in cell-free assays, respectively.

TW-37 Chemical Structure

CAS No. 877877-35-5

Selleck's TW-37 has been cited by 44 publications

Purity & Quality Control

Choose Selective Bcl-2 Inhibitors

Other Bcl-2 Products

Biological Activity

Description TW-37 is a novel nonpeptide inhibitor to recombinant Bcl-2, Bcl-xL and Mcl-1 with Ki of 0.29 μM, 1.11 μM and 0.26 μM in cell-free assays, respectively.
Targets
Mcl-1 [1]
(Cell-free assay)
Bcl-2 [1]
(Cell-free assay)
Bcl-xL [1]
(Cell-free assay)
0.26 μM(Ki) 0.29 μM(Ki) 1.11 μM(Ki)
In vitro

TW-37 targets the BH3-binding groove in Bcl-2 where proapoptotic Bcl-2 proteins bind, and shows higher affinity and selectivity for Bcl-2 and Mcl-1 over Bcl-xL with Ki values of 0.29 μM, 0.26 μM and 1.11 μM, respectively. [1] In vitro, TW-37 shows significant anti-proliferative and pro-apoptotic effect in a de novo chemo-resistant WSU-DLCL2 lymphoma cell line and primary cells obtained from a lymphoma patient without effects on normal peripheral blood lymphocytes. [1] TW-37 exhibits the inhibitory effect on both cell growth and cell death in endothelial cell with IC50 of approximately 1.8 μM without effect on the fibroblasts exposed to the same concentration range as the endothelial cells. In addition, TW37 also shows the anti-proliferation effects in MCF-7, LNCaP, and SLK tumor cell lines with the same or lower concentration range than those required to inhibit endothelial cell growth. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
human JAR cell MmDCS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NGnqOnlKdmirYnn0bY9vKG:oIHj1cYFvKEqDUjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUKuOkBvVQ>? NYHxTZFvW0GQR1XS
human Ca9-22 cell NEfjVGNIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MV3Jcohq[mm2aX;uJI9nKGi3bXHuJGNiQS1{MjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUOuPFIhdk1? NY\EXYN5W0GQR1XS
human CHL-1 cell MXHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MXvJcohq[mm2aX;uJI9nKGi3bXHuJGNJVC1zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MUGuPUBvVQ>? MnT3V2FPT0WU
human A549 cell NInqWmFIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MWrJcohq[mm2aX;uJI9nKGi3bXHuJGE2PDliY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1zND6wPUBvVQ>? MXvTRW5ITVJ?
human RKO cell MYrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M2rVU2lvcGmkaYTpc44hd2ZiaIXtZY4hWkuRIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MUWuNVchdk1? NELtNWNUSU6JRWK=
human GCIY cell NF[yfZRIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MXjJcohq[mm2aX;uJI9nKGi3bXHuJGdEUVliY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1{MD64N{BvVQ>? NWX3dVd7W0GQR1XS
human BHT-101 cell MX7Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M4H4N2lvcGmkaYTpc44hd2ZiaIXtZY4hSkiWLUGwNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVIyNjh|IH7N M1XoNXNCVkeHUh?=
human Hs-578-T cell M{HURWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M1LHOGlvcGmkaYTpc44hd2ZiaIXtZY4hUHNvNUe4MXQh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0zOy53OTDuUS=> M37uRXNCVkeHUh?=
human SK-UT-1 cell MVnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NETPdpBKdmirYnn0bY9vKG:oIHj1cYFvKFONLWXUMVEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0zQC54ODDuUS=> NGfuS2ZUSU6JRWK=
human NB7 cell NYTvW4dsT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M1rY[mlvcGmkaYTpc44hd2ZiaIXtZY4hVkJ5IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MkmuNlghdk1? NFrVbphUSU6JRWK=
human YKG-1 cell MkHKS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M4TuemlvcGmkaYTpc44hd2ZiaIXtZY4hYUuJLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yPU44PiCwTR?= MnLIV2FPT0WU
human HuH-7 cell MljOS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NGrqXIlKdmirYnn0bY9vKG:oIHj1cYFvKEi3SD23JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9N|IvQDJibl2= MV;TRW5ITVJ?
human SAS cell NGPzXWlIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M2G3eGlvcGmkaYTpc44hd2ZiaIXtZY4hW0GVIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;M{OuNVghdk1? NIO5Z4FUSU6JRWK=
human UACC-62 cell MmDES5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NFX2ZXRKdmirYnn0bY9vKG:oIHj1cYFvKFWDQ1OtOlIh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0{PC5|NTDuUS=> MYLTRW5ITVJ?
human AGS cell MWXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NYfTUmo{UW6qaXLpeIlwdiCxZjDoeY1idiCDR2OgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zO{42OyCwTR?= MnLhV2FPT0WU
human SK-MEL-30 cell M3S1Zmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MXHJcohq[mm2aX;uJI9nKGi3bXHuJHNMNU2HTD2zNEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVM4Njl5IH7N NFvDdlhUSU6JRWK=
human A427 cell NWrsTlV[T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NEHIXplKdmirYnn0bY9vKG:oIHj1cYFvKEF2MkegZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME20OE43QSCwTR?= NVvKU|FnW0GQR1XS
human DU-145 cell NX;CWGlqT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NEe4O21KdmirYnn0bY9vKG:oIHj1cYFvKESXLUG0OUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVUzNjF|IH7N MoO5V2FPT0WU
human HCT-116 cell NEDnenBIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MnfOTY5pcWKrdHnvckBw\iCqdX3hckBJS1RvMUG2JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OVIvPjZibl2= M2H2NnNCVkeHUh?=
human A673 cell NV\ieG1ET3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MWrJcohq[mm2aX;uJI9nKGi3bXHuJGE3PzNiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD13Mz64OUBvVQ>? MV7TRW5ITVJ?
human SF126 cell MVvHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NEnD[XJKdmirYnn0bY9vKG:oIHj1cYFvKFOIMUK2JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OVcvODdibl2= MX;TRW5ITVJ?
human SW872 cell NUK3ZnJmT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M1Ttd2lvcGmkaYTpc44hd2ZiaIXtZY4hW1d6N{KgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21PE46KG6P MmmxV2FPT0WU
human NCI-H1581 cell Mm[0S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MWnJcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KMUW4NUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVY4NjZ2IH7N M3zQNHNCVkeHUh?=
human SK-MEL-5 cell M3LOVWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NG[1dVFKdmirYnn0bY9vKG:oIHj1cYFvKFONLV3FUE02KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PjlwMkWgcm0> MYXTRW5ITVJ?
human CP50-MEL-B cell MmeyS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MlO5TY5pcWKrdHnvckBw\iCqdX3hckBEWDVyLV3FUE1DKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PjlwNUmgcm0> M{XsNHNCVkeHUh?=
human YH-13 cell MoHFS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MXXJcohq[mm2aX;uJI9nKGi3bXHuJHlJNTF|IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;N{CuOVkhdk1? NIfwPHlUSU6JRWK=
human LXF-289 cell MVPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M4n5V2lvcGmkaYTpc44hd2ZiaIXtZY4hVFiILUK4PUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVczNjh3IH7N MVnTRW5ITVJ?
human MC-IXC cell NUTGWYhrT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M4fJN2lvcGmkaYTpc44hd2ZiaIXtZY4hVUNvSWjDJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9O|UvOzNibl2= MnLrV2FPT0WU
human NB14 cell NFnre49Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= MWjJcohq[mm2aX;uJI9nKGi3bXHuJG5DOTRiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD15Nj60OUBvVQ>? NIL5OVNUSU6JRWK=
human HEC-1 cell MnTmS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NXzqenRVUW6qaXLpeIlwdiCxZjDoeY1idiCKRVOtNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVgyNjN5IH7N NXHHR455W0GQR1XS
human U-87-MG cell MX;Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MXnJcohq[mm2aX;uJI9nKGi3bXHuJHUuQDdvTVegZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME24Nk4zPCCwTR?= MlPRV2FPT0WU
human HOS cell NGTHdGFIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NGWzSWJKdmirYnn0bY9vKG:oIHj1cYFvKEiRUzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUi0MlcyKG6P MlTUV2FPT0WU
human HUTU-80 cell NYH3UZB1T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MkTHTY5pcWKrdHnvckBw\iCqdX3hckBJXVSXLUiwJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9PFcvODFibl2= NYnBOGl1W0GQR1XS
human A375 cell NXzzRWlOT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NEjjNmFKdmirYnn0bY9vKG:oIHj1cYFvKEF|N{WgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME24PE45OyCwTR?= Mm\HV2FPT0WU
human A204 cell NVTUW3MzT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NHvzS2RKdmirYnn0bY9vKG:oIHj1cYFvKEF{MESgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME25O{45PCCwTR?= M{XNTHNCVkeHUh?=
human GB-1 cell MWfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M3jFfGlvcGmkaYTpc44hd2ZiaIXtZY4hT0JvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUm4MlY6KG6P Ml;HV2FPT0WU
human MDA-MB-231 cell Ml3wS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M4DEPGlvcGmkaYTpc44hd2ZiaIXtZY4hVUSDLV3CMVI{OSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTBwMUC4NFch|ryP NEDsNINUSU6JRWK=
human SW982 cell MnvVS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NWLET2F7UW6qaXLpeIlwdiCxZjDoeY1idiCVV{m4NkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOTFyNzFOwG0> NY\G[4pXW0GQR1XS
human SW756 cell MlrSS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MVTJcohq[mm2aX;uJI9nKGi3bXHuJHNYPzV4IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD6xNVI{PiEQvF2= NVO0XVF3W0GQR1XS
human MG-63 cell M{PRPGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MUTJcohq[mm2aX;uJI9nKGi3bXHuJG1INTZ|IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD6xNVI1QCEQvF2= M3XkVnNCVkeHUh?=
human Daoy cell NYXTbIp7T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MXPJcohq[mm2aX;uJI9nKGi3bXHuJGRid3liY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLkG0NFc{KM7:TR?= MVfTRW5ITVJ?
human MDA-MB-453 cell NEi2SGZIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MnHwTY5pcWKrdHnvckBw\iCqdX3hckBOTEFvTVKtOFU{KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC5zNUG4PEDPxE1? NWPxUFdNW0GQR1XS
human HT-144 cell NI[xfIpIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NVfiSJFbUW6qaXLpeIlwdiCxZjDoeY1idiCKVD2xOFQh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjF3MkCxJO69VQ>? NWeyUohlW0GQR1XS
human LoVo cell MoTPS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M{DSb2lvcGmkaYTpc44hd2ZiaIXtZY4hVG:YbzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuNVYxQTNizszN MX;TRW5ITVJ?
human NY cell M3;pUmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M3;wXWlvcGmkaYTpc44hd2ZiaIXtZY4hVlliY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLkG3O|YzKM7:TR?= NH;pXGZUSU6JRWK=
human SW1783 cell MX\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? Ml7jTY5pcWKrdHnvckBw\iCqdX3hckBUXzF5OEOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlIyOzBzIN88US=> M4PPTHNCVkeHUh?=
human A2780 cell MoPvS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M3SwbmlvcGmkaYTpc44hd2ZiaIXtZY4hSTJ5OECgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlIyQDR4IN88US=> MUjTRW5ITVJ?
human MDA-MB-361 cell NWT6XohkT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MVTJcohq[mm2aX;uJI9nKGi3bXHuJG1FSS2PQj2zOlEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjJ{NkSg{txO MVPTRW5ITVJ?
human RPMI-2650 cell Ml65S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MYLJcohq[mm2aX;uJI9nKGi3bXHuJHJRVUlvMk[1NEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOjN6M{Gg{txO MYHTRW5ITVJ?
In vivo TW-37 shows a maximum tolerated dose (MTD) of 40 mg/kg for three i.v. injections in severe combined immunodeficient (SCID) mice when given alone, and enhances tumor inhibitory effect of cyclophosphamide-doxorubicin-vincristine-prednisone (CHOP) regimen. [1] TW-37, administrated by i.v. produces the antiangiogenic effect by decreasing the density of functional human microvessels in the severe combined immunodeficient mouse model of human angiogenesis. [2] The combination of TW-37 and MEK inhibitors synergistically block melanoma cell growth in mice by a significant reduction in tumor volume and tumor mass. [3]

Protocol (from reference)

Kinase Assay:[1]
  • Fluorescence polarization-based binding assay for recombinant Bcl-2, Bcl-XL, and Mcl-1 protein :

    For this assay, the 21-residue BH3 peptide QEDIIRNIARHLAQVGDSMDR derived from Bid labeled with 6-carboxyfluorescein succinimidyl ester (FAM-Bid) and recombinant proteins derived from human Bcl-2,Bcl-X L,and Mcl-1 are employed. It is determined that FAM-Bid has a Ki of 11 nM to Bcl-2 protein,25 nM to Bcl-XL protein,and 5.7 nM to Mcl-1 protein. The competitive binding assay for Bcl-XL is same as that for Bcl-2 with the following exceptions: 30 nM Bcl-XL protein and 2.5 nM FAM-Bid peptide in the following assay buffer [50 mM Tris-Bis (pH 7.4) and 0.01% bovine gamma-globulin].

Cell Research:[2]
  • Cell lines: HDMECs
  • Concentrations: 0 - 100 μM
  • Incubation Time: 96 hours
  • Method: The sulforhodamine B (SRB) cytotoxicity assay is used as described. Briefly, optimal cell density for cytotoxicity assay is determined by growth curve analysis. HDMECs are seeded in a 96-well plate and allowed to adhere overnight. Drug or control is diluted in EGM2-MV and layered onto cells, which are allowed to incubate for times as indicated in the figures. Alternatively, HDMECs are coincubated with TW37 and 0 to 100 ng/mL recombinant human VEGF (rhVEGF)165 or 0 to 100 ng/mL recombinant human CXCL8. Cells are fixed on the plates by addition of cold trichloroacetic acid (10% final concentration) and incubation for 1 hour at 4 °C. Cellular protein is stained by addition of 0.4% SRB in 1% acetic acid and incubation at room temperature for 30 minutes. Unbound SRB is removed by washing with 1% acetic acid and the plates are air dried. Bound SRB is resolubilized in 10 mM unbuffered Tris-base and absorbance is determined on a microplate reader at 560 nm. Test results are normalized against initial plating density and drug-free controls. Data are obtained from triplicate wells per condition and are representative of at least three independent experiments
Animal Research:[3]
  • Animal Models: Athymic NCr-nu/nu mice bearing SK-Mel-147 melanoma xenografts
  • Dosages: ~40 mg/kg
  • Administration: Administered via i.v. or i.p.

Solubility (25°C)

In vitro

In vivo

Add solvents to the product individually and in order
(Data is from Selleck tests instead of citations):
30% propylene glycol, 5% Tween 80, 65% D5W
For best results, use promptly after mixing.

30 mg/mL

Chemical Information

Molecular Weight 573.7
Formula

C33H35NO6S

CAS No. 877877-35-5
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles CC(C)C1=CC=CC=C1CC2=CC(=C(C(=C2O)O)O)C(=O)NC3=CC=C(C=C3)S(=O)(=O)C4=CC=CC=C4C(C)(C)C

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy TW-37 | TW-37 supplier | purchase TW-37 | TW-37 cost | TW-37 manufacturer | order TW-37 | TW-37 distributor